Webinar
A new look at R&D productivity: how small changes to key levers can dramatically impact cost per output
calendar

December 1, 2022

Calendar
clock

2:00pm - 3:00pm

GMT

Register

View all IQVIA events

Despite increasing annual new drug approval volumes in recent years, R&D productivity varies dramatically among major pharmaceutical companies. The attrition-loaded cost of achieving a new product approval is an important indicator of productivity – and a critical factor in achieving top-tier performance.

IQVIA has developed an analytical model which allows us to examine the cost per approval indicator at an individual company level for a cohort of major pharmaceutical companies, and to track how that metric has changed over the last 10 years. Using the model, we can also demonstrate how dramatic improvements in R&D productivity could be achieved with relatively small changes to underlying R&D levers such as cycle times. Indeed, in recent years, a number of companies have reported R&D productivity initiatives to identify and target such levers – contributing to improved company performance and analyst perceptions of R&D.

In this webinar, we discuss the above topics to highlight what we believe to be a major opportunity for companies to systematically and proactively address areas for potential improvement, for the benefit of their own stakeholders and for the industry as a whole.

Contact Us